Trial · NCT03852719
Results by group33
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 33
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Combined Response at Week 48 | Delayed Treatment | 2.0 | 95% Confidence Interval 0.0 to 10.4 | percentage of participants | |
| Percentage of Participants With Combined Response at Week 48 | Bulevirtide 2 mg/Day | 44.9 | 95% Confidence Interval 30.7 to 59.8 | percentage of participants | |
| Percentage of Participants With Combined Response at Week 48 | Bulevirtide 10 mg/Day | 48.0 | 95% Confidence Interval 33.7 to 62.6 | percentage of participants | |
| Percentage of Participants With Undetectable HDV RNA at Week 48 | Delayed Treatment | 0 | 95% Confidence Interval 0.0 to 7.0 | percentage of participants | |
| Percentage of Participants With Undetectable HDV RNA at Week 48 | Bulevirtide 2 mg/Day | 12.2 | 95% Confidence Interval 4.6 to 24.8 | percentage of participants | |
| Percentage of Participants With Undetectable HDV RNA at Week 48 | Bulevirtide 10 mg/Day | 20.0 | 95% Confidence Interval 10.0 to 33.7 | percentage of participants | |
| Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48 | Delayed Treatment | 11.8 | 95% Confidence Interval 4.4 to 23.9 | percentage of participants | |
| Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48 | Bulevirtide 2 mg/Day | 51.0 | 95% Confidence Interval 36.3 to 65.6 | percentage of participants | |
| Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48 | Bulevirtide 10 mg/Day | 56.0 | 95% Confidence Interval 41.3 to 70.0 | percentage of participants | |
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 48 | Delayed Treatment | 0.87 | 95% Confidence Interval -0.79 to 2.53 | kPa | |
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 48 | Bulevirtide 2 mg/Day | -3.06 | 95% Confidence Interval -4.67 to -1.45 | kPa | |
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 48 | Bulevirtide 10 mg/Day | -3.16 | 95% Confidence Interval -4.88 to -1.43 | kPa | |
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 48 | Delayed Treatment / /Bulevirtide 10 mg/Day | -3.36 | 95% Confidence Interval -4.60 to -2.12 | kPa | |
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 96 | Bulevirtide 2 mg/Day | -4.31 | 95% Confidence Interval -5.54 to -3.08 | kPa | |
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 96 | Bulevirtide 10 mg/Day | -4.88 | 95% Confidence Interval -6.11 to -3.65 | kPa | |
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 96 | Delayed Treatment/Bulevirtide 10 mg/Day | -4.20 | 95% Confidence Interval -5.41 to -2.98 | kPa | |
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 144 | Bulevirtide 2 mg/Day | -5.24 | 95% Confidence Interval -6.85 to -3.63 | kPa | |
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 144 | Bulevirtide 10 mg/Day | -4.03 | 95% Confidence Interval -5.67 to -2.40 | kPa | |
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 192 | Bulevirtide 2 mg/Day | -3.74 | 95% Confidence Interval -5.28 to -2.20 | kPa | |
| Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 192 | Bulevirtide 10 mg/Day | -3.70 | 95% Confidence Interval -5.27 to -2.14 | kPa |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03852719/results